A novel synthetic peptide for the specific treatment of lupus: clinical effects and mechanism of action.
Mozes
Edna
E
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. edna.mozes@weizmann.ac.il
Sela
Uri
U
Sharabi
Amir
A
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001323:Autoantibodies / Q000276:immunology; D022801:Complementarity Determining Regions / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D010446:Peptide Fragments / Q000494:pharmacology*; D011948:Receptors, Antigen, T-Cell / Q000037:antagonists & inhibitors / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
D001323:Autoantibodies; D022801:Complementarity Determining Regions; C481963:FOXJ1 protein, mouse; D000071316:Forkhead Box Protein O3; D051858:Forkhead Transcription Factors; C474033:FoxO3 protein, mouse; D010446:Peptide Fragments; D011948:Receptors, Antigen, T-Cell